EMA recommends approval of Eurartesim for uncomplicated malaria
The European Medicines Agency or EMA said Friday that it has recommended the approval of Eurartesim, from Sigma-tau Industrie Farmaceutiche Riunite SpA, a fixed combination product consisting of dihydroartemisinin and piperaquine phosphate, for the treatment of uncomplicated Plasmodium falciparum malaria.
The Economic Community of West African States says it is poised to eliminate Malaria in the sub-region by 2015.